GLG News by Adderall XR Prescribers (US)

1. Shire has withdrawn patches that had defective patch liners. 2. This defect is not related to safety or efficacy issues. 3. The cost to Shire is less than $10 million.

Eli Lilly reported that the prodrug mGluR2/3 agonist LY2140023 met all end points in a randomized, three-armed, double-blind, placebo controlled, 4-week proof-of-concept trial that enrolled schizophrenia patients.

Lundbeck’s LUAA21004 and LU24530 are among several drugs licensed to Takeda, the others earlier in development, that may offer unique biological and clinical profiles as compared with existing antidepressants and anti-anxiety drugs. Lundbeck’s platform includes about 6 drugs, covering a potentially...

1. Lu AA21004 and Lu AA24530 are two compounds with a great deal of potential and will be co-marketed jointly by Takeda and Lundbeck. 2. Lu AA21004 is the more advanced of the compounds and is currently in phase II development for the treatment of major depression. 3. The compounds potentially address...

1. LY2140023 is an antipsychotic agent that is a metabotropic glutamate 2/3 receptor agonist. This agent has a new mechanism of action that is efficacious in treating schizophrenia and potentially other neuropsychiatric conditions. 2. LY2140023 in addition to separating from placebo in a statistically...

1. The Actelion agent (ACT-078573) is not a sedative-hypnotic but is an orexin receptor antagonist. 2. This agent may have a safety and tolerability profile that is better than the sedative-hypnotics. 3. The above implications would make Actelion a prime acquisition for a big-pharma company with a less...

1. A recent psychiatric journal reported a higher incidence of bipolar disorders in the pediatric population and a subsequent increase in antipsychotic medication use in children. 2. Assessment tools (bipolar disorder questionnaires) have significantly increased awareness of bipolar disorder symptomatology...

1. Pediatric bipolar disorder is an urgent public health problem 2. There is added recognition that this can occur in children 3. Very difficult to diagnose-need comprehensive assessment to ensure accurate diagnosis and as importantly not 'overdiagnosing'

I am a psychiatrist in private practice in a major metropolitan area that has a diverse population. I offer the following observations based on my clinical post-marketing experience. I have already prescribed Vyvanse to a few hundred patients. My observations: 1. Duration of action: This is a huge issue....

1. This agent despite a favorable side effect profile lacks efficacy as compared to other antipsychotic agents already approved by the FDA. 2. This is a temporary setback for Wyeth. 3. This in the long run is to Wyeth's advantage as such an agent would have done poorly in a competitive atypical antipsychotic...